• Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

BBP2:GR

0.603 EUR 0.004 0.66%

As of 04:55:03 ET on 11/24/2014.

Snapshot for Vernalis PLC (BBP2)

Open: 0.607 Day's Range: 0.585 - 0.627 Volume: 0
Previous Close: 0.607 52wk Range: 0.280 - 0.654 1-Yr Rtn: +110.10%

Stock Chart for BBP2

No chart data available.
  • BBP2:GR 0.603
  • 1D
  • 1M
  • 1Y
0.607
Interactive BBP2 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for BBP2

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (GBP) (ttm) -
Est. EPS (GBP) (12/2014) -0.0200
Est. PEG Ratio -
Market Cap (M EUR) 266.71
Shares Outstanding (M) 442.30
30 Day Average Volume 263
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/01/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for BBP2

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for BBP2

Vernalis plc is a revenue generating development stage pharmaceutical company which has a broad pipeline of research and development programs. The Company is focused on developing products for the US prescription cough and cold market. The Company derives pipeline candidates both from collaborations with global pharmaceutical businesses and their own research activities.

David MackneyChief Financial OfficerIan GarlandChief Executive Officer
Tom ParkerSenior VP:Commercial OperationsPascal BorderiesSenior VP:Medical Affairs
More Company Profile & Key Executives for BBP2

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil